Clinical trials: Cytomegalovirus Disease
Cancer
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have…
- Trial name
- NCT00769613
- Testing
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Graft Versus Host Disease, Nonneoplastic Condition
T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
RATIONALE: An infusion of cytomegalovirus-specific T lymphocytes may prevent or reduce cytomegalovirus infection during the first year after a donor stem cell transplant.
- Trial name
- NCT00986557
- Testing
- adoptive immunotherapy, alemtuzumab, in vitro-treated peripheral blood lymphocyte therapy
- Where
- United Kingdom
- Volunteers
- 78 people
- Sponsor
- University Hospital Birmingham
Viral Disease, Cytomegalovirus Infection
In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir
The infection with cytomegalovirus (CMV) is the first cause of congenital neurological handicap of infectious origin. It is probable that the neonatal viral load is correlated with becoming of infected new-born babies.
- Trial name
- CYMEVAL (NCT01037712)
- Testing
- Valacyclovir (ZELITREX)
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cytomegalovirus Disease
Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
A prospective, randomized safety and efficacy study of Certican® as add-on therapy against CMV disease in renal transplant recipients OBJECTIVES: Primary Objective: To demonstrate efficacy of Certican® as add-on therapy against…
- Trial name
- Certi-CMV (NCT00828503)
- Testing
- Certican (everolimus) + valganciclovir, Valganciclovir
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Marcus Saemann
Cytomegalovirus Infections, Inflammatory Bowel Diseases
MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus
The main objective of this study is to demonstrate the relevance of Valganciclovir on recurrent bouts of cryptogenic inflammatory bowel diseases with infection by cytomegalovirus (CMV).
- Trial name
- NCT00237653
- Testing
- Valganciclovir
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Grenoble
Cytomegalovirus Retinitis, HIV Infections
A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV Therapy
The purpose of this study is to see if it is safe to stop maintenance therapy in HIV-positive patients with treated and healed CMV retinitis (eye disease) who have responded well to anti-HIV (antiretroviral) therapy.
- Trial name
- NCT00000905
- Where
- 25 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Arterial Occlusive Diseases, Atherosclerosis
Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction
The purpose of this study is to investigate whether the susceptibility of subjects to atherosclerosis is influenced by prior CMV exposure, whether the susceptability to endothelial dysfunction in patients with and in patients…
- Conditions
- Arterial Occlusive Diseases, Atherosclerosis, Coronary Disease, Cytomegalovirus Infections
- Trial name
- NCT00001531
- Where
- United States
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
Efficacy of Elevated CD4 Counts on CMV Retinitis
Some patients with HIV/AIDS suffer from a dangerous viral infection of the retina (and other organs) called cytomegalovirus infection (CMV). The medications currently used to treat CMV all have serious side effects.
- Trial name
- NCT00091884
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Eye Institute (NEI)
HIV Infections, Gastrointestinal Diseases
Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease
PRIMARY: To compare the frequency of and time to relapse of Cytomegalovirus (CMV) gastrointestinal disease following foscarnet induction therapy only versus induction plus maintenance therapy.
- Trial name
- NCT00002145
- Testing
- Foscarnet sodium
- Where
- 15 sites in United States
- Volunteers
- 145 people
- Sponsor
- Astra USA
Cytomegalovirus Infections
Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection
OBJECTIVES: I. Evaluate the efficacy of ganciclovir (12 mg/kg per day) versus no treatment in neonates with symptomatic congenital cytomegalovirus infection with central nervous system disease.
- Trial name
- NCT00004278
- Testing
- ganciclovir
- Volunteers
- 130 people
- Sponsor
- National Center for Research Resources (NCRR)
Cytomegalovirus Infections
Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease
OBJECTIVES: I. Evaluate the safety, tolerance, and potential efficacy of 3 doses of human anti-cytomegalovirus (CMV) monoclonal antibody SDZ MSL-109 (MOAB MSL-109) in the treatment of newborns with congenital CMV infection and no…
- Trial name
- NCT00004642
- Testing
- SDZ MSL-109
- Sponsor
- National Center for Research Resources (NCRR)
Cytomegalovirus Retinitis, Acquired Immunodeficiency Syndrome
Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis
OBJECTIVES: I. Evaluate the safety and efficacy of intravenous cidofovir in patients with small peripheral cytomegalovirus retinitis. II. Obtain safety and efficacy data related to different dosages of cidofovir.
- Trial name
- NCT00004794
- Testing
- cidofovir
- Volunteers
- 90 people
- Sponsor
- National Center for Research Resources (NCRR)